Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.34 |
| ▸ | CDK2 | P24941 | 5/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 2/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | MET | P08581 | 4/20 | 0.31 |
| ▸ | RBP4 | P02753 | 3/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891697 | 0.92 | IGF1R (0.49) | IGF1RCCNA2CDK2CCNA1EP300 | |
| SCHEMBL1889843 | 0.90 | IGF1R (0.62) | IGF1RCCNA2CDK2CCNA1LMNA | |
| SCHEMBL1889646 | 0.89 | IGF1R (0.53) | IGF1RCCNA2CDK2CCNA1LMNA | |
| SCHEMBL1892216 | 0.88 | CCNA2 (0.39) | IGF1RCCNA2CDK2CCNA1 | |
| SCHEMBL1889972 | 0.88 | IGF1R (0.49) | IGF1RCCNA2CDK2CCNA1MET | |
| SCHEMBL1889034 | 0.88 | IGF1R (0.49) | IGF1RCCNA2CDK2CCNA1MET | |
| SCHEMBL1894289 | 0.87 | IGF1R (0.48) | IGF1RCCNA2CDK2CCNA1RBP4 | |
| SCHEMBL1890038 | 0.85 | IGF1R (0.61) | IGF1RCCNA2CDK2CCNA1LMNA | |
| SCHEMBL1883520 | 0.84 | IGF1R (0.52) | IGF1RCCNA2CDK2CCNA1EP300 | |
| SCHEMBL1890569 | 0.84 | IGF1R (0.51) | IGF1RCCNA2CDK2CCNA1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-22 | — | — | US | disclosed |
| US-7947686-B2 | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K3, MAP3K1, MAP3K19 | IGF1R 760/4885CCNA2 1202/4885CDK2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.